POSNOC is a large clinical trial exploring new treatments for breast cancer
Positive sentinel node: adjuvant therapy alone versus adjuvant therapy plus clearance or axillary radiotherapy.
POSNOC is a 10 year clinical study looking at the armpit treatment provided to women diagnosed with early stage breast cancer. It will involve more than 50 hospitals and 1900 women across the UK.
For women with early breast cancer undergoing surgery, the surgeon removes one or two lymph glands from the armpit on the side of the cancer to check if the cancer has spread to the lymph glands. For about a quarter of women, the breast cancer has spread to the lymph glands. Currently, these women undergo further treatment to their armpit (axillary treatment). This is either a second operation to remove all the lymph glands in the armpit or radiotherapy to the armpit.
Further armpit treatment is the focus of this study as it can carry risks and potential side effects. Symptoms can include:
swelling in the arm and shoulder
- impairment of the arm
- shoulder stiffness
The aim of the study is to find out if armpit treatment is of benefit in women with cancer spread to one or two lymph glands, receiving one or more of drug treatments (chemotherapy or endocrine therapy).
Award for ICPV Member
Many congratulations to ICPV member Margaret Grayson. On 21 April 2018 she received the Iris Colvin Lifetime Achievement Award for Health, presented by the Women’s Forum of Northern Ireland. This is very well deserved for her tireless work in furthering cancer research especially in Northern Ireland.
Warwick Clinical Trials
12 members of ICPV attended a residential Clinical Trials Course at the University of Warwick from 17th to 19th April 2018. The course was run by Professor Janet Dunn and covered the different types of studies undertaken; consent; trial design; statistics and bringing a drug to market. One of the highlights of the course was a visit to the West Midlands Surgical Training Centre where delegates had the privilege of seeing real body parts and having basic anatomy explained to them by the team. The delegates would like to thank Professor Janet Dunn for her outstanding enthusiasm and for her generous hospitality.
Open letter calling on Government to prioritise interests of cancer patients in Brexit negotiations
ICPV have come together with 18 other cancer charities to put our names to an open letter to Government. We want Government to prioritise seeking continued alignment with the EU drug licensing
process and Clinical Trials Regulation after Brexit. It is hoped this letter will be published in the national press in the near future.
See below to read.
2017 Summer School
The 2017 ICPV Summer School was held over two days in June at Stirling University. The theme of the event was Cancer Survivorship and Living Well Cancer. Click below for details of the course. More details.
A snapsot video of the the 2016 course is now available on YouTube VOICE2016
At the BACR/ECMC conference in July Maggie Wilcox and Mairead Mackenzie were persuaded to speak to the camera. Maggie gave a background to ICPV and our aims and objectives. While Mairead focused on her specific interests and activities. To view follow the links below.
July 2016 Conferences
ICPV members were busy this week with two conferences. The BACR/ECMC Joint Meeting on Therapeutic Interventions for Cancer Prevention was held in Bristol July18-19. The UK Breast Cancer Research Symposium was held in London from July 22-23. Click here for more information.
UK Therapeutic Cancer Prevention Network (UKTCPN)
An update from this new group was presented to the ECMC Annual Network Meeting in May 2016. Click here to download and read.
Call for immediate change to European Paediatric Medicine Regulation to save more lives of children and teens with cancer.
A few basic changes to European Law could speed up access to newer, kinder and potentially better drugs for more children and teenagers with cancer. Click to Sign the petition
Two years on from the start pioneering TRACERx lung cancer study. Click here For the latest news and patient views on this study.